An emerging therapeutic strategy to tackle cancer is nanobodies – small, single-domain antibody fragments derived from heavy-chain-only antibodies.
Nanobodies, also known as single-domain antibodies or VHHs, are small, highly stable, and specific antibody fragments.
Bulk B cell analysis is a powerful tool for antibody discovery because it provides a snapshot of the entire B cell population at a given time.
In pharmacokinetics, standard curves are used to determine the concentration of a drug in biological fluids such as blood or plasma.
ADCs are essentially a new class of drugs that combine the targeting properties of antibodies with the cell-killing ability of drugs.
Monoclonal antibodies are revolutionizing therapeutics with their precision and specificity, allowing for safer treatment of a variety of diseases...
StackWave Affinity v15 Announcement - Titration and Dose Response Experiments
The sunk cost fallacy can affect our decision making around LIMS, other software, and antibody discovery technology purchases.
StackWave Affinity™ takes a fundamentally different approach than other software solutions to the unique challenges of Antibody Discovery teams.
Every year, StackWave delivers a steady stream of improvements to our Affinity antibody discovery solution, and 2022 was no exception.